A Phase 1 interventional study of Upadacitinib in Juvenile Idiopathic Arthritis (JIA), sponsored by AbbVie. Active, not recruiting at 35 sites in 10 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-08-03.
Sponsored by AbbVie · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Arthritis, Juvenile by AbbVie — 2 open to participants now, 3 under way, 2 of them phase 3. Arthritis, Juvenile · AbbVie.
Among the 10 studies in Arthritis, Juvenile by AbbVie, this one is the only one that started in 2019, is the only one in phase 1, and was the 7th registered.
366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.
Browse Arthritis, Juvenile studies →2 of the 10 studies in Arthritis, Juvenile by AbbVie are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Australia, Canada and 6 more countries
Ages 5–17
AbbVie · Sites in United States, Argentina, Australia and 14 more countries
Ages 1–17
By country, each count listing its studies:
Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 124 is above the median of 52 across 231 interventional studies indexed under Arthritis, Juvenile.
Median enrollment 46 across the 5 interventional studies, 70 across the 5 observational. Of the 7 that completed or were terminated, 4 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Arthritis, Juvenile by AbbVie, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a study to evaluate pharmacokinetics, safety and tolerability of upadacitinib in pediatric participants with polyarticular course juvenile idiopathic arthritis. This study consists of three parts: Part 1 is multiple-cohort study that consists of two sequential multiple dose groups. Participants benefiting from the study drug with no ongoing adverse events of special interest or serious adverse events will have option to enroll in Part 2. Part 2 is open-label, long term extension study to evaluate safety and tolerability. Part 3 is an additional safety cohort to evaluate long-term safety and tolerability. Participants \<18 years of age who are ongoing in Parts 2 and 3 will participate in an 104 week open-label extension of the study in Part 4.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants of age group 12 to \<18 years administered with upadacitinib dose A (weight dependent) as described in the protocol.
Drug: Upadacitinib
Participants of age group 12 to \<18 years administered with upadacitinib dose B (weight dependent) as described in the protocol.
Drug: Upadacitinib
Participants of age group 6 to \<12 years administered with upadacitinib dose A (weight dependent) as described in the protocol.
Drug: Upadacitinib
Participants of age group 2 to \<6 years administered with upadacitinib dose A (weight dependent) as described in the protocol.
Drug: Upadacitinib
Participants of age group 2 to \<18 years administered with upadacitinib dose A as described in the protocol.
Drug: Upadacitinib
Upadacitinib is administered as an oral solution or tablet as described in protocol.
Also known as: ABT-494
Treatment Emergent Adverse Events (TEAEs)
Adverse Event is defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product.
Time frame: Up to approximately 260 weeks
Part 1: Maximum observed plasma concentration (Cmax)
Cmax is defined as the maximum observed plasma concentration for upadacitinib.
Time frame: Day 7
Part 1: Time to maximum observed plasma concentration (Tmax)
Tmax is defined as the time to maximum plasma concentration (Cmax) of upadacitinib.
Time frame: Day 7
Part 1: Area under plasma concentration versus time curve during a dosing interval (AUCtau)
The area under the plasma concentration-time curve is a method of measurement of the total exposure of a drug in plasma.
Time frame: Day 7
Part 1: Apparent oral clearance at steady state (CL/F)
Clearance is defined as the volume of plasma cleared of the drug per unit time.
Time frame: Day 7
Part 1: Half-life
Half life of updadacitinib will be determined using non-compartmental method.
Time frame: Day 7
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2019 (actual). Primary completion is estimated for Dec 2028, 114 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Upadacitinib